[Regression of severe periarticular calcifications during treatment with bisphosphonate in a dialysis patient].
Treatment with etidronate, 400 mg daily, induced total regression of severe, disabling periarticular calcifications during a treatment period of 42 months in a patient with chronic kidney disease on dialysis treatment. All symptoms disappeared. No adverse effects were recorded during the treatment. Thus, treatment with etidronate can induce regression of the periarticular calcifications which comprise a complication to chronic renal failure.
Obad
Damir
D
Regionshospitalet Holstebro, Medicinsk Afdeling, Denmark. damir@dadlnet.dk
Larsen
Niels A
NA
Pedersen
Erling B
EB
D050071:Bone Density Conservation Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002114:Calcinosis / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000209:etiology; D012968:Etidronic Acid / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications* / Q000628:therapy; D008297:Male; D008875:Middle Aged; D011859:Radiography; D006435:Renal Dialysis / Q000009:adverse effects; D016896:Treatment Outcome
D050071:Bone Density Conservation Agents; D012968:Etidronic Acid